Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club

Inward Investment
Return to: PBR Home | Inward Investment | News
Search Refinements

Inward Investment News

View news from other Pharmaceutical sectors:
91-105 of 412 results
CytoDyn to purchase Progenics PRO 140 anti-HIV drug
By PBR Staff Writer
CytoDyn has entered into an agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140, for $3.5m.
Inward Investment > News
Boehringer purchases rights to Funxional's FX125L compound
By PBR Staff Writer
Boehringer Ingelheim and Funxional Therapeutics have signed an agreement under which Boehringer will acquire the global rights to Funxional's FX125L compound and somatotaxin program.
Inward Investment > News
Synergy, Callisto sign definitive merger agreement
By PBR Staff Writer
Callisto Pharmaceuticals will merge with Synergy Pharmaceuticals following a definitive merger agreement between both the companies.
Inward Investment > News
GlaxoSmithKline to takeover HGS
By PBR Staff Writer
GlaxoSmithKline (GSK) has signed a definitive agreement to acquire Human Genome Sciences (HGS) for $14.25 per share in cash.
Inward Investment > News
Amgen acquires KAI pharmaceuticals
By PBR Staff Writer
US based pharmaceutical company, Amgen has acquired KAI Pharmaceuticals.
Inward Investment > News
Genstar Capital takes over ERT
By PBR Staff Writer
Genstar Capital has completed the acquisition of the ERT in a take-private transaction valued at approximately $400m.
Inward Investment > News
Bristol-Myers Squibb to take over Amylin pharmaceuticals
By PBR Staff Writer
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn.
Inward Investment > News
Cornerstone buys EKR Therapeutics
By PBR Staff Writer
Cornerstone Therapeutics has acquired a privately-held specialty pharmaceutical company focused on the acute-care hospital setting, EKR Therapeutics.
Inward Investment > News
InterMune completes sale of Actimmune
By PBR Staff Writer
InterMune has completed divestiture of Actimmune (interferon gamma-1b) to Vidara Therapeutics, a part of an international specialty pharmaceutical group of companies with operations in Ireland and the US.
Inward Investment > News
AstraZeneca takes over Ardea Biosciences
By PBR Staff Writer
AstraZeneca, a biopharmaceutical company, has completed the purchase of a US-based biotechnology company, Ardea Biosciences.
Inward Investment > News
Valeant Pharmaceuticals to acquire OraPharma
By PBR Staff Writer
Valeant Pharmaceuticals has signed an agreement to buy OraPharma, an oral health company, from Water Street Healthcare Partners.
Inward Investment > News
Amgen takes over more than 99% of MN Pharmaceuticals shares
By PBR Staff Writer
Amgen has completed the acquisition of more than 99% of the shares of Mustafa Nevzat Pharmaceuticals (MN Pharmaceuticals), a privately held Turkish company.
Inward Investment > News
Takeda America takes over URL Pharma
By PBR Staff Writer
Takeda America Holdings, a wholly owned subsidiary of Takeda Pharmaceutical Company, has acquired URL Pharma for an upfront payment of $800m.
Inward Investment > News
Eli Lilly opens new diabetes-focused R&D center in China
By PBR Staff Writer
Eli Lilly and Company has officially opened the Lilly China Research and Development Center (LCRDC), a diabetes-focused research and development center in Shanghai, China.
Inward Investment > News
InterMune signs deal with Vidara Therapeutics to divest Actimmune
By PBR Staff Writer
InterMune has signed a definitive agreement with Vidara Therapeutics International (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in $55m cash transaction and a two-year royalty stream.
Inward Investment > News
91-105 of 412 results